Document is current
Any future updates will be listed below
-
Authors
Su, Yin https://orcid.org/0000-0003-1364-1598
Li, Jing
Wang, Chenguang
Zhang, Xunmin
Hou, Sheng
Guo, Huaizu
Deng, Chenhui
Ou, Lun
Wang, Jinwei
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04779892 at ClinicalTrials.govnct03478111 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis
https://doi.org/10.1007/s12325-022-02396-8
Documents that mention this clinical trial
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
https://doi.org/10.1007/s40744-023-00544-2
Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis
https://doi.org/10.1007/s12325-022-02396-8
-
Funding
Funding for this research was provided by:
National Key R&D Program of China (2021YFC2501700)
- License Information
-
More Information
Article History
Received: 19 October 2022
Accepted: 29 November 2022
First Online: 6 January 2023
